Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead deepens Galapagos ties with $5.1 billion deal, including $3.95 billion upfront and $1.1 billion equity investment to raise its stake to 22%.
Gilead and Galapagos enter a transformative 10-year, $5.1 billion R&D collaboration, with Gilead investing $3.95 billion in equity and paying $1.1 billion in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Gilead invested $5.1 billion to deepen its collaboration with Galapagos, comprising a $3.95 billion upfront payment and a $1.1 billion equity investment (raising its stake from 12.3% to 22%). The 10-year agreement gave Gilead access to six clinical-phase assets, 20 preclinical programs, and option rights on all future Galapagos pipeline programs. For filgotinib specifically, Galapagos gained greater involvement in global strategy and European commercialization, with costs shared 50:50 (replacing the prior 80:20 split).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Galapagos NV (this deal) | 2019 | $5.1B | 25 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2019 deals · Gilead Sciences Inc. deals · Gastroenterology deals